Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.61 |
| ▸ | CES1 | P23141 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | GABRP | O00591 | 1/20 | 0.52 |
| ▸ | GABRD | O14764 | 1/20 | 0.52 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.52 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.52 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.52 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.52 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.52 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.52 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.52 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.52 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.52 |
| ▸ | GABRE | P78334 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.52 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.52 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.52 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL304519 | 1.00 | CES2 (0.61) | CES2CES1TSHRGABRPGABRD | |
| SCHEMBL12491655 | 1.00 | CES2 (0.61) | CES2CES1TSHRGABRPGABRD | |
| SCHEMBL8365391 | 1.00 | CES2 (0.61) | CES2CES1TSHRGABRPGABRD | |
| SCHEMBL12492077 | 1.00 | CES2 (0.61) | CES2CES1TSHRGABRPGABRD | |
| SCHEMBL1260777 | 1.00 | CES2 (0.61) | CES2CES1TSHRGABRPGABRD | |
| SCHEMBL25212375 | 1.00 | CES2 (0.61) | CES2CES1TSHRGABRPGABRD | |
| SCHEMBL10188550 | 1.00 | CES2 (0.61) | CES2CES1TSHRGABRPGABRD | |
| SCHEMBL242069 | 1.00 | CES2 (0.61) | CES2CES1TSHRGABRPGABRD | |
| SCHEMBL6501 | 1.00 | — | — | |
| SCHEMBL11964239 | 1.00 | CES2 (0.61) | CES2CES1TSHRGABRPGABRD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1642901-B1 | Novel erythromycin derivatives | PFIZER PROD INC (US) | 2007-10-31 | — | — | EP | disclosed |
| EP-1642901-A1 | Novel erythromycin derivatives | Pfizer Products Inc. (US) | 2006-04-05 | — | — | EP | disclosed |
| US-7015203-B2 | Erythromycin analogs and azalides, particularly ones with novel C-13 substituents; for treating bacterial and protozoa infections | PFIZER INC. (US) | 2006-03-21 | — | — | US | disclosed |
| EP-1602727-A2 | Novel erythromycins and process for their preparation | Biotica Technology Limited (GB) | 2005-12-07 | — | — | EP | disclosed |
| EP-0909327-B1 | ERYTHROMYCINS AND PROCESS FOR THEIR PREPARATION | BIOTICA TECH LTD (GB) | 2005-06-01 | — | — | EP | disclosed |
| US-6825171-B2 | MACROLIDE ANTIBIOTIC USEFUL IN THE TREATMENT OF A BROAD SPRECTRUM OF BACTERIAL INFECTIONS AND PROTOZOA INFECTIONS | PFIZER, INC. | 2004-11-30 | — | — | US | disclosed |
| US-20040092459-A1 | Novel macrolides | PFIZER INC. | 2004-05-13 | — | — | US | disclosed |
| US-20040067897-A1 | Novel erythromycin derivatives | PFIZER INC. | 2004-04-08 | — | — | US | disclosed |
| US-6472371-B1 | Macrolides | PFIZER, INC. | 2002-10-29 | — | — | US | disclosed |
| US-6437151-B2 | FERMENTATION; CULTURE PRODUCT | BIOTICA TECHNOLOGY LIMITED (GB) | 2002-08-20 | — | — | US | disclosed |
| US-20010016598-A1 | Fermenting suitable organisms such as saccharopolyspora erythraea in the presence of a carboxylic acid | LEADLAY PETER FRANCIS (GB) | 2001-08-23 | — | — | US | disclosed |
| US-6271255-B1 | USEFUL AS ANTIBACTERIAL AND ANTIPROTOZOAL AGENTS IN INFECTIONS IN MAMMALS, FISH, AND BIRDS | BIOTICA TECHNOLOGY LIMITED (GB) | 2001-08-07 | — | — | US | disclosed |
| EP-1044208-A1 | ERYTHROMYCIN DERIVATIVES | Pfizer Products Inc. (US) | 2000-10-18 | — | — | EP | disclosed |
| EP-1044207-A1 | NOVEL MACROLIDES | Pfizer Products Inc. (US) | 2000-10-18 | — | — | EP | disclosed |
| EP-0755912-B1 | Process for the preparation of 2-substituted cyclopentanones | BAYER AG (DE) | 1999-09-08 | — | — | EP | disclosed |
| WO-1999035156-A1 | NOVEL MACROLIDES | PFIZER PRODUCTS INC. (US) | 1999-07-15 | — | — | WO | disclosed |
| WO-1999035157-A1 | NOVEL ERYTHROMYCIN DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1999-07-15 | — | — | WO | disclosed |
| EP-0755912-A2 | Process for the preparation of 2-substituted cyclopentanones | BAYER AG (DE) | 1997-01-29 | — | — | EP | disclosed |
| US-4064110-A | FROM 5-ALKOXYMETHYL-1,3,4-DIOXAZOL-2-ONES, ALKALI METAL CARBOXYLATE CATALYST | BAYER AKTIENGESELLSCHAFT (DT) | 1977-12-20 | — | — | US | disclosed |
| US-4017606-A | CYTOSINE ARABINOSIDE AND HYDROGENATED PYRIMIDINE NUCLEOSIDES | THE UPJOHN COMPANY (US) | 1977-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067897-A1 | Novel erythromycin derivatives | GIPR, MLNR, PGC | CES2 724/4885CES1 230/4885TSHR 938/4885 |
| US-20010016598-A1 | Fermenting suitable organisms such as saccharopolyspora erythraea in the presence of a carboxylic acid | COASY, RPL13, DCXR | CES2 335/4885CES1 333/4885TSHR 3774/4885 |
| US-20040092459-A1 | Novel macrolides | CYP51A1, RPS12, AZI2 | CES2 905/4885CES1 967/4885TSHR 2876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.